A wealth of evidence supports the driving role of Hippo pathway in linking liver fibrosis and cancer: (1) the functional crosstalk of Hippo pathway with TGF-β and NOTCH pro-oncogenic pathways has been reported early during liver fibrosis [32, 83–85]; and (2) YAP and TAZ support chronic inflammation, which is a major inducer of liver fibrosis, and liver cancer. This evidence concerns the gene YAP1 and Hepatic fibrosis.